BiotechTube
GlycoTherapeutics

GlycoTherapeutics

Leiden, Netherlands· Est.
glycotherapeutics.eu
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

GlycoTherapeutics is an early-stage biotech company developing novel therapies that target glycan-mediated immune suppression to enhance the efficacy of cancer immunotherapies. Founded in 2022 as a university spin-off, the company has secured over €1.5 million in non-dilutive grant funding and is building its scientific and business team. While still in the preclinical research phase, its unique focus on the glycobiology of the tumor microenvironment positions it in a promising niche within the immuno-oncology landscape.

OncologyInfectious Disease

Technology Platform

Proprietary glycobiology platform focused on disrupting glycan-mediated interactions that suppress the immune system in the tumor microenvironment, aiming to enhance the efficacy of immunotherapies.

Opportunities

GlycoTherapeutics operates in the large and growing immuno-oncology market, targeting the significant unmet need of patients who do not respond to current therapies.
Its novel focus on glycobiology offers a potentially differentiated mechanism to overcome immune resistance.
Successful validation could lead to lucrative partnerships or acquisition by larger pharmaceutical companies seeking next-generation combination therapies.

Risk Factors

The company faces high scientific risk as its novel glycobiology approach is unproven in clinical settings.
As a pre-revenue startup, it is dependent on securing future venture capital funding to advance beyond grant-supported research.
There is also competitive risk from larger players who may enter the space if the target biology is validated.

Competitive Landscape

GlycoTherapeutics competes in the broad tumor microenvironment modulation space but is differentiated by its specific focus on glycan-mediated immunosuppression, a relatively underexplored niche. Competitors include companies targeting other immune checkpoints, cytokines, and cellular components of the TME. Its main competitive advantage is its deep academic foundation and proprietary insights into glycobiology.

More companies in Immunotherapy / Immuno-Oncology →More companies in Netherlands →